933 POSTER Immunotherapy in patients with recurrent epithelial ovarian cancer with the anti-idiotypic monoclonal antibody ACA125 (AGO-OVAR, phase I/II trial)

首页> 外文期刊>European Journal of Cancer Supplements >933 POSTER Immunotherapy in patients with recurrent epithelial ovarian cancer with the anti-idiotypic monoclonal antibody ACA125 (AGO-OVAR, phase I/II trial)

【24h】

933 POSTER Immunotherapy in patients with recurrent epithelial ovarian cancer with the anti-idiotypic monoclonal antibody ACA125 (AGO-OVAR, phase I/II trial)

机译：抗独特型单克隆抗体ACA125对复发性上皮性卵巢癌患者的933 POSTER免疫疗法（AGO-OVAR，I / II期试验）

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2005年第2期| 共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR [J] . J Pfisterer, A du Bois, J Sehouli, Annals of Oncology . 2006 ,第10期

机译：复发性卵巢癌患者的抗独特型抗体abagovomab。 AGO-OVAR的第一阶段试验
2. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). [J] . Meier W, du Bois A, Reuss A Gynecologic Oncology: An International Journal . 2009 ,第2期

机译：拓扑替康与烷基化剂海洛因相比，上皮性卵巢癌患者在一线铂/紫杉醇化疗后12个月内复发。一项由Arbeitsgemeinschaft妇科肿瘤卵巢癌研究小组（AGO-OVAR）进行的前瞻性随机III期试验。
3. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha 2b in patients with recurrent epithelial ovarian cancer [J] . Dijkgraaf E. M., Santegoets S. J. A. M., Reyners A. K. L., Annals of oncology: official journal of the European Society for Medical Oncology . 2015 ,第10期

机译：一期临床试验将卡铂/阿霉素与托珠单抗，抗IL-6R单克隆抗体和干扰素-α2b联合用于复发性上皮性卵巢癌患者
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Determination of the potential use of beta-glucan as an adjuvant for monoclonal antibody immunotherapy of cancer. [D] . Hong, Feng. 2002

机译：确定β-葡聚糖作为癌症单克隆抗体免疫疗法佐剂的潜在用途。
6. PIPAC-OV3: A multicenter open-label randomized two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian fallopian tube or primary peritoneal cancer [O] . Naoual Bakrin, Clemens Tempfer, Giovanni Scambia, 2018

机译：PIPAC-OV3：一项多中心开放标签随机三臂III期临床试验对加压铂-腹膜内气雾剂化疗（PIPAC）与单独化疗的铂-铂类患者对顺铂和阿霉素的无进展生存期有影响耐药的复发性上皮性卵巢癌输卵管癌或原发性腹膜癌
7. Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission [O] . René H. Verheijen, Leon F. Massuger, Benedict B. Benigno, 2006

机译：在手术定期完全缓解后，用钇-90标记的钇-90标记的HMFG1鼠单克隆抗体腹膜内治疗的III期试验

933 POSTER Immunotherapy in patients with recurrent epithelial ovarian cancer with the anti-idiotypic monoclonal antibody ACA125 (AGO-OVAR, phase I/II trial)

著录项

相似文献

相关主题

期刊订阅